Genmab
Tracked across 3 events · 34 articles · First seen Apr 03, 2026 · Last active Jun 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Impact: Genmab announced positive safety data from its Phase 1/2 RAINFOL-01 trial for Rina-S in combination with bevacizumab for advanced ovarian cancer, supporting further development of its investigational drug.
Apr 13, 2026 · 8 articles
Tech
Genmab A/S announced new data from a post-hoc subgroup analysis of its pivotal Phase 3 EPCORE FL-1 trial, evaluating epcoritamab in combination with rituximab and lenalidomide (epcoritamab + R2) for adult patients with relapsed or…
Impact: Genmab A/S announced positive new data from its Phase 3 EPCORE FL-1 trial, demonstrating consistent efficacy and safety of epcoritamab in treating follicular lymphoma, which is expected to positively impact its stock price and market position.
Jun 11, 2026 · 6 articles
Business
These articles provide daily market recaps, detailing the performance of US futures for the S&P 500>>> and Dow Jones Industrial Average>>>, European stock indices like the STOXX Europe 600>>>, FTSE 100 Index>>>, CAC 40>>>, and…
Impact: Genmab>>> lost 4% in one trading session, reflecting negative investor sentiment.
May 18, 2026 · 20 articles
100
Genmab announced new dataGenmab EPCORE FL-1 Trial Data
80
Genmab presented results European Hematology AssociationGenmab EPCORE FL-1 Trial Data
NEWSDESK
Track Genmab live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard